| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905; and Center for Translational Medicine in Women’s Health, Tumor Vaccine Group, University of Washington, Seattle, WA 98109
Studies in cancer patients have suggested that breast tumors recruit regulatory T cells (Tregs) into the tumor microenvironment. The extent to which local Tregs suppress antitumor immunity in breast cancer is unknown. We questioned whether inhibiting systemic Tregs with an IL-2 immunotoxin in a model of neu-mediated breast cancer, the neu-transgenic mouse, could impact disease progression and survival. As in human breast cancer, cancers that develop in these mice attract Tregs into the tumor microenvironment to levels of 
10–25% of the total CD4+ T cells. To examine the role of Tregs in blocking immune-mediated rejection of tumor, we depleted CD4+CD25+ T cells with an IL-2 immunotoxin. The treatment depleted Tregs without concomitant lymphopenia and markedly inhibited tumor growth. Depletion of Tregs resulted in a persistent antitumor response that was maintained over a month after the last treatment. The clinical response was immune-mediated because adoptive transfer of Tregs led to a complete abrogation of the therapeutic effects of immunotoxin treatment. Further, Treg down-modulation was accompanied by increased Ag-specific immunity against the neu protein, a self Ag. These results suggest that Tregs play a major role in preventing an effective endogenous immune response against breast cancer and that depletion of Tregs, without any additional immunotherapy, may mediate a significant antitumor response.
This article has been cited by other articles:
|
|
 |
|
  N. Larmonier, J. Cantrell, C. LaCasse, G. Li, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky, and E. Katsanis Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression J. Leukoc. Biol., April 1, 2008; 83(4): 1049 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Behrens, W. M. Wagner, C. J. Krco, C. L. Erskine, K. R. Kalli, J. Krempski, E. A. Gad, M. L. Disis, and K. L. Knutson The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity Blood, February 1, 2008; 111(3): 1472 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Leon, K. Garcia, J. Carneiro, and A. Lage How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies J. Immunol., November 1, 2007; 179(9): 5659 - 5668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kalinski Treg cells, cancer vaccines: timing is everything Blood, November 1, 2007; 110(9): 3090 - 3091. [Full Text] [PDF]
|
|
|
|
|
|
M. T. Litzinger, R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity Blood, November 1, 2007; 110(9): 3192 - 3201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Jacob, Y.-c. M. Kong, C. Meroueh, D. P. Snower, C. S. David, Y.-S. Ho, and W.-Z. Wei Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells Cancer Res., July 15, 2007; 67(14): 7020 - 7027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dang, K. L. Knutson, V. Goodell, C. dela Rosa, L. G. Salazar, D. Higgins, J. Childs, and M. L. Disis Tumor Antigen-Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming Clin. Cancer Res., March 15, 2007; 13(6): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors Cancer Res., February 1, 2007; 67(3): 1326 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lu, K. L. Knutson, E. Gad, and M. L. Disis The Tumor Antigen Repertoire Identified in Tumor-Bearing Neu Transgenic Mice Predicts Human Tumor Antigens Cancer Res., October 1, 2006; 66(19): 9754 - 9761. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
